Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, Inc. (INBX), bought 9,940 shares at $84.07 ($840K) on 2026-10-14, disclosed to the SEC on 2026-10-14.
CEO Mark Lappe purchased 2,470 shares of INBX for $207,655, signaling confidence in the stock's current valuation. This buy comes as the stock has retraced significantly from its 52-week high, presenting a potential entry point for long-term investors.
The stock is down 5.46% over the last five days and 20.35% over the past month, trading at $88.33. Despite a 153.73% one-year gain, the current price is still 42.52% below the 52-week high of $153.68.
Insufficient data — needs manual review
The stock has a high beta of 3.82, indicating significant volatility. Additionally, the short interest represents 31.14% of the float, which could lead to increased selling pressure if the stock reverses.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $84.07 | 2,449 | $206K | 24.5% |
| 2 | $84.07 | 2,470 | $208K | 24.7% |
| 3 | $85.00 | 2,451 | $208K | 24.8% |
| 4 | $85.00 | 2,470 | $210K | 25.0% |
| 5 | $85.76 | 100 | $9K | 1.0% |
| Total | $84.55 avg | 9,940 |
| $840K |
| 100% |